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ABSTRACT
Migraine is a paroxysmal pain disorder managed with abortive therapy during a pain
attack, prophylactic therapy to prevent attacks, and often a combination of both. Calcitonin generelated peptide (CGRP) and its receptor have a role in the provocation of migraines, and
therefore have been targeted in the development of both preventive and abortive therapies.
However, there is limited research investigating concomitant use of the therapies. This study will
examine the safety and efficacy of oral rimegepant when used for acute treatment concomitantly
with a monoclonal antibody (mAb) targeting the CGRP ligand or receptor for the preventive
treatment of migraine. A biphasic trial with a randomized, double-blind, placebo-controlled
Primary Phase and an open label Secondary Phase will assess efficacy as measured by freedom
from pain at 2 hours. The results of this study have the potential to improve and expand the
management approaches used for migraine patients.
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CHAPTER 1: INTRODUCTION
1.1 Background
Migraine is a disabling disorder which is estimated to affect approximately 15% of the
global population.1 Migraine is characterized by a painful unilateral headache attack often
associated with nausea, vomiting, photophobia, and phonophobia.2 An increased frequency of
migraine headache days correlates with increased disability and results in decreased quality of
life involving both negative social and psychological impacts.3
Although the definitive underlying pathophysiology of migraine is unknown, the
inflammatory peptide, calcitonin gene-related peptide (CGRP), and its receptor, expressed in
both the peripheral and central nervous system including trigeminovascular pathways, have been
identified as having a role in the provocation of migraines.4 This system has been targeted in the
search for new efficacious and safe migraine treatments. One of the more promising classes are
small molecule CGRP receptor antagonists, also called gepants. Such a small molecule
antagonist can either compete with the initial CGRP C-terminal binding event and block the
activation of the receptor or potentially displace bound CGRP and deactivate the receptor.5 One
of the gepants, rimegepant (Nurtec-ODT [Biohaven Pharmaceuticals, New Haven, CT]), was
found to be significantly more effective than placebo for acute treatment of migraine, as
measured by pain freedom and reduction of most bothersome symptom (MBS) two hours after
intake.2 It was approved for acute treatment of migraine by the Food and Drug Administration
(FDA) in February 2020 (Biohaven Pharmaceutical Company Holding Ltd., 2020).
The advent and approval of rimegepant was a significant development in the acute
treatment of migraine. Although many abortive treatments for migraine are available, their
efficacy and tolerability vary greatly among migraine patients. One of the more widely and wellestablished acute treatments are triptans. Sumatriptan is the most commonly used acute treatment
1

for migraine attacks in the United States of America (US).6 However, pain freedom at 2 hours
after drug intake, the primary outcome in most clinical trials for acute treatment of migraine, is
only experienced by 12-40% of patients depending on the triptan used.2 Also, triptans are
contraindicated in patients with coronary artery disease, uncontrolled hypertension, and
cerebrovascular disease.5 The gepants’ proposed mechanism of action involves the inhibition of
vasorelaxant responses to CGRP in the middle meningeal arteries, and they are less potent in
antagonizing the vasodilatory responses in the coronary arteries.2,7,8 Therefore, rimegepant may
be a suitable alternative for patients who are unable to use or do not currently achieve pain
freedom from triptans or other abortive treatments. It continues to be important to consider the
natural cardioprotective effects of CGRP as well as any pre-existing cardiovascular or
cerebrovascular risk factors when using drugs that target this system.
The CGRP system has also become a target for preventive migraine therapy. Several new
preventive interventions have been introduced and are increasingly being utilized by patients
with migraine. The primary focus involves monoclonal antibodies (mAbs) that target the CGRP
system and unlike other existing preventives, are administered via monthly injection (or
quarterly injection for fremanezumab [Ajovy] and eptinezumab [Vyepti]). These FDA approved
preventives include erenumab-aooe (Aimovig [Amgen, Thousand Oaks, CA and Novartis,
Switzerland]), galcanezumab-gnlm (Emgality [Eli Lilly, Indianapolis, IN]), fremanezumab-vfrm
(Ajovy [Teva, Israel]), and eptinezumab-jjmr (Vyepti [Lundbeck Seattle Biopharmaceuticals,
Inc., Bothell, WA] which have all demonstrated safety and efficacy in trials.9-12 Galcanezumab,
fremanezumab, and eptinezumab neutralize some portion of circulating α-CGRP and β-CGRP
ligands which prevent it from signaling.5 Erenumab is unique from the other CGRP preventives
in that it blocks the CGRP receptor instead of the peptide itself.13 Erenumab and fremanezumab
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are approved for prevention in adults with either the episodic (<15 migraine days per month) or
chronic (>14 migraine days per month) form of migraine. Fremanezumab has also demonstrated
efficacy in patients with documented failure of up to four migraine preventive medication
classes.11 Galcanezumab is approved for migraine prevention in those with at least four
migraines per month and it is the only CGRP mAb that is approved for cluster headache
prevention.13 In contrast to the other CGRP mAbs that are injected subcutaneously, eptinezumab
is administered intravenously every 3 months and approved for the episodic or chronic form of
migraine.12,14 The advent of this new class of preventive treatment in migraine is welcomed by
both patients and providers. Existing preventive options for migraine consist of a variety of
antihypertensive, antidepressant, and antiepileptic medications, which have numerous side
effects and on which less than 50% of patients experience a 50% or greater reduction in their
monthly attack frequency.4 The CGRP mAbs also have ranged from 43-62% of patients
achieving 50% reduction, but the ease of intermittent dosing as well as low incidence and mild to
moderate severity of reported adverse events make them a desirable alternative.4,13 Furthermore,
CGRP antibodies show a low risk for drug-drug interactions and hepatotoxicity, which can be
important for patients using multiple medications.4 Complete remission from migraine is
uncommon, even with this breakthrough preventive treatment, and acute migraine attacks will
still occur in the majority of patients on CGRP antibody therapy. Although at a reduced
frequency and intensity, these remaining attacks are often debilitating and require acute
treatment.15
1.2 Statement of the Problem
Given the concomitant development of gepants and mAbs, both of which act on the CGRP
system, it begs the questions—Would patients using both experience greater benefit? Is such a
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combination safe? Targeting the CGRP system for both acute and prophylactic migraine
treatment has the potential to generate a stronger antimigraine effect, however, a possible
increase in side effects would have to be thoroughly assessed as well.2 Published reports of the
concomitant use of oral rimegepant for acute treatment and a mAb for prevention are limited. A
small case series demonstrated possible efficacy in treating refractory migraine with concomitant
rimegepant and erenumab.16 Following those promising cases, an open-label sub-study of 13
migraine patients simultaneously using rimegepant with erenumab or either anti-CGRP mAbs,
fremanezumab or galcanezumab, showed no serious adverse events; efficacy was not reported,
however.17 Therefore, further study in the form of a randomized controlled trial to investigate the
safety and efficacy of rimegepant in the setting of concomitant mAb therapy is necessary. If
shown to be effective as well as safe, this therapeutic approach may have clinical implications
for migraine treatment. Exploration of concomitant CGRP therapy may provide the best
opportunity to expand evidence-based migraine management and to improve quality of life in
migraine patients.
1.3 Goals and Objectives
The goal of this study is to investigate the efficacy and safety of rimegepant for acute
migraine treatment when used concomitantly with a CGRP ligand- or receptor-targeted mAb
compared to use without a mAb. Efficacy will be determined by freedom from pain at 2 hours
after administration of rimegepant.
1.4 Hypothesis
When using rimegepant as an abortive intervention, adult subjects on an anti-CGRP or
anti-CGRP receptor mAb preventive (subcutaneous or intravenous injection) will have a
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different incidence proportion of freedom from pain at 2 hours compared to those who have
never used a mAb preventive.
1.5 Definitions
•

Rimegepant: CGRP receptor antagonist, single dose 75 mg oral dissolving tablet

•

Adult: ages 18-65 (inclusive)

•

Anti-CGRP or anti-CGRP receptor monoclonal antibody migraine preventives:
erenumab, galcanezumab, fremanezumab, or eptinezumab

•

Freedom from pain: On a 0 to 3 pain severity numerical rating scale (0=none, 1=mild,
2=moderate, 3=severe), the reduction from moderate (2) or severe (3) at the time of drug
administration to no pain (0).
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CHAPTER 2: LITERATURE REVIEW
2.1 Introduction
During the period of July 2020 to July 2021, a comprehensive systematic literature search
was conducted using repeated searches of PubMed, Scopus, Web of Science, and
clinicaltrials.gov databases. Assistance was much appreciated and provided by the librarians at
the Yale School of Medicine. Searches were conducted using the following combination of
MeSH terms: “migraine”, “calcitonin gene-related peptide”, “CGRP”, “gepant[s]”,
“rimegepant”, “monoclonal antibod[y][ies]”, “erenumab”, “galcanezumab”, “fremanezumab”,
“eptinezumab”, and included brand and alternative names for each medication. Reference lists of
all studies were looked at to identify additional pertinent literature. In this review, relevant
clinical studies (including case series and conference poster presentations), systematic reviews,
and meta-analyses were included. Preference was given to articles detailing concomitant use of
CGRP monoclonal antibodies (mAbs) and rimegepant, and randomized controlled trials (RCTs)
investigating efficacy of rimegepant.
The literature search demonstrates the novelty of concomitant use of rimegepant with
CGRP mAb therapy. Empirical studies documenting their use are inherently limited due to being
case series. For this reason, RCTs investigating efficacy of the medications and the classes to
which they belong to were also included to obtain the maximal amount of information existing
around their clinical use thus far. The novelty of the medications establishes opportunities for
research, however this also reveals the necessity of designing a study which is both feasible and
realistic for the stage at which the drugs can be safely studied. Without advancing to a RCT to
investigate the concomitant use of the medications, there will be a lack of data to support clinical
benefit, thus justifying the need for the proposed study.
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2.2 Mechanisms of CGRP Blockade
Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide that binds to a
CGRP receptor and causes potent vasodilation, including in cranial vasculature and specifically
within the trigeminal ganglion.1 The peptide is known to be released during migraine attacks and
intravenous infusions of CGRP have been shown to induce migraine-like headaches in migraine
patients.2 It has been proposed that elevated levels of CGRP may lead to sensitization of
neuronal circuits such that usual sensory inputs (light, sounds, tastes, odors) are experienced as
bothersome.3 The mAbs likely target CGRP and its receptors within the trigeminal ganglion and
due to their molecular weight of 150 kilo Daltons (kDa) and structure they are unlikely to cross
the blood brain barrier (BBB).1-3 Although gepants weigh 0.2-1 kDa, their main target is also
thought to be outside of the BBB since only a small percentage of gepant is detected in
cerebrospinal fluid compared to plasma following administration in non-human primates.2
The CGRP receptor is a G-protein-coupled receptor which is formed by calcitonin
receptor-like receptor (CLR) and a receptor activity-modifying protein 1 (RAMP1), therefore it
is often referred to as CLR/RAMP1 receptor.3 Rimegepant is a small molecule antagonist with
two proposed mechanisms: competition with the initial binding of CGRP to its receptor, blocking
activation of the receptor, or displacement of bound CGRP, effectively deactivating the receptor.

Figure 1. Mechanisms of CGRP blockade by a small molecule CGRP Receptor Antagonist (dark blue): competition
with the initial CGRP ligand (red) C-terminal binding event, preventing N-terminal agonist insertion (D to F), and
displacement of bound CGRP ligand (E to F).3
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In order to achieve efficacy with either proposed mechanism, high enough circulating plasma
levels are needed as well as balanced physical properties of receptor affinity, protein binding,
pharmacokinetics, and safety.3 In these regards, rimegepant has been optimized. For example, its
standard oral dissolving tablet (ODT) formulation has been shown to accelerate relief of
migraine through more rapid exposure, showing difference of effect from placebo as early as 15
minutes following administration and statistically significant by 1 hour for pain relief and return
to normal function.3 From a safety perspective, the increased potency of rimegepant in
antagonizing the CGRP receptors in the middle meningeal arteries as compared to the coronary
arteries may prevent cardiovascular side effects and allow for a broadened patient population to
use them in comparison to triptans.2,4,5
The migraine preventive mAb, erenumab, binds with high affinity to and antagonizes the
CLR/RAMP1 receptor, while galcanezumab, fremanezumab, and eptinezumab bind to the
neuropeptide itself, neutralizing some portion of the ligand preventing it from signaling through
the CLR/RAMP1 receptor.3,6 The mAbs’ high selectivity for either CGRP or the CGRP receptor
reduces the risk of off-target effects and possible drug to drug interactions. They also have a very
long plasma half-life, allowing for once monthly or quarterly injection.2 Given that they are
tolerated well with infrequent administration, this leads to higher treatment adherence rates
compared to other preventives.7 Also, the long half-life of the monoclonal antibodies may target
the high levels of CGRP associated with medication overuse headache, a fairly common problem
among migraine patients, and alleviate this as well.2 Unfortunately, the intended preventive
effect varies among patients, where some have no response, some have a small reduction in their
number of monthly headache days, and some have a near or actual complete response.2 In a large
trial investigating efficacy of erenumab, 40% of participants achieved >50% reduction in
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monthly migraine days, and no participants were rid of migraine attacks entirely.7 Given this,
acute treatment will still be required and herein lies an opportunity to investigate the concomitant
use of gepants and mAbs.
2.3 Concomitant Use of Gepants and Monoclonal Antibodies (mAbs)
Especially for difficult-to-treat patients, a possible therapeutic approach has emerged
involving the combination of gepants and monoclonal antibodies (mAbs).8 Acting on the CGRP
pathway in two ways, there’s potential for a stronger anti-migraine effect. For example, it’s
possible that surges of CGRP during migraine attacks may be better targeted by the small
molecule gepants with quicker onset of action and short half-life while the biologic mAbs’
longer half-life offer sustained migraine prevention.3 The medications offer differentiation in
their action and therefore increase coverage for the migraine patient. However, combination
treatment may have potential limitations which would need to be considered in the design of the
present trial. Not all patients have the same degree of response to receptor or peptide blockade
offered by mAb preventives, so it would be plausible to expect similar variation in response to
antagonism of the CGRP receptor with rimegepant.9 To better characterize the response to
combination therapy, one stratified analysis would compare the response to rimegepant seen in
positive versus less positive responders to preventive mAbs. Another potential mechanistic
conflict to consider is that with blocking of the CGRP receptor, CGRP can still bind other
receptors (e.g., amylin receptor 1, AMY1) and induce a migraine effect. Conversely, if the
CGRP neuropeptide is blocked, it is still possible for other peptides (e.g., adrenomedullin) to
activate the CGRP receptor albeit with lower affinity than CGRP.2 Both proposed conflicts, if
true, would preclude optimal migraine management. Lastly, the chronic blockade of the CGRP
receptor could result in a compensatory overexpression of CGRP receptors leading to tolerance
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of the medications over time.4 These possible barriers will not be elucidated in this proposed
trial, however being aware of the potential shortcomings, as well as the strengths, of a treatment
modality on a molecular level is essential when expanding this area of study.
Two case series exist describing the potential for concomitant use of a CGRP mAb and
CGRP receptor antagonist in the treatment of migraine. In this first example, a case series
presents two subjects participating in a long-term safety study of rimegepant for acute treatment
(after FDA approval); both were started on monthly erenumab in addition to existing
rimegepant.10 Both subjects self-reported decades of medically refractory migraine. While on
erenumab, every migraine attack the subjects treated with rimegepant was successfully relieved
and no other acute rescue medications were required.10 More so, no adverse events were
experienced by either subject. This study, although purely observational and limited by size, was
a breakthrough in that it brought forth the reasonable possibility that CGRP signaling could be
targeted acutely (i.e., by a gepant) on a background of chronic inhibition (i.e., by a mAb). It is
theorized the 2 agents differ in half life and potency, allowing rimegepant to provide additional
benefits to ongoing mAb therapy.11 The mAbs have a half-life of 27-30 days, whereas
rimegepant has a significantly shorter 11 hour half-life. In addition, rimegepant was found to be
16 times more potent than erenumab at antagonism of CGRP-mediated cyclic adenosine
monophosphate (cAMP) signaling in whole-cell assays, so combination therapy may provide an
additive benefit in blocking the intracellular cascades leading to vasodilatory effects.12
Additional studies to verify and uncover the sources for the efficacy of combination therapy are
warranted.
The second case series reports on 13 subjects with migraine on a stable dose of a CGRP
mAb who treated acute attacks with rimegepant. The goal was to assess the rate of on-treatment
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adverse events. No subjects had serious adverse events, adverse events leading to
discontinuation, or aminotransferase levels >3x the upper limit of normal.13 Given that the
combination treatment was well tolerated, the authors called for studies of larger patient
populations to confirm their findings. This study is limited by its open label design and short
duration of follow up. In regards to mechanism, the study proposes a theory that the CGRP
receptor occupancy may decrease between injections of a CGRP mAb, which would lead to
increases in unbound CGRP levels in the plasma.13 Prior modeling studies have indicated that
during the month following an injection of a ligand targeted mAb (i.e. galcanezumab,
fremanezumab, eptinezumab), CGRP plasma levels first drop then return to baseline with up to
36% to 55% of CGRP unbound with the potential to induce breakthrough attacks by binding to
their receptor.14 Therefore, rimegepant acting on the receptor itself is likely to provide a targeted
benefit in aborting these acute attacks. In addition, with a progressive rise in CGRP plasma
levels throughout the month, this suggests there may be an optimal period during which patients
would benefit, or conversely, a period where potent blockade poses risk associated with
excessive blockade of CGRP activity.
2.4 Review of Rimegepant Efficacy Trials
Although there are no published RCTs investigating concomitant use of CGRP mAbs and
rimegepant, multiple studies have examined the relationship between rimegepant and freedom
from pain at 2 hours, as well as other secondary variables to be analyzed in this proposed trial.
Two similar randomized, double-blind, placebo-controlled, multi-center phase 3 trials, both with
over 1,000 subjects, demonstrated that a single 75 mg dose of rimegepant was more effective
than placebo in freedom from pain at 2 hours —21% versus (vs) 11%, Risk Difference (RD) 10.4
(95% Confidence Interval (CI) 6.5 to 14.2), p<0·000115 and 19.6% vs 12.0%, RD 7.6 (95% CI
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3.3 to 11.9), p<0.00116 —and freedom from the most bothersome symptom (MBS) at 2 hours—
35% vs 27%, RD 8.3 (95% CI 3.4 to 13.2), p=0·000915 and 37.6% vs 25.2%, RD 12.4 (95% CI
6.9 to 17.9), p<0.00116. There was also a positive response shown at 60 minutes post-dose and
continuing through 48 hours post-dose suggesting rimegepant’s duration of effect might provide
advantages over triptans and other gepants.15 In addition, one randomized dose-ranging trial of
rimegepant compared the intervention to placebo with sumatriptan as an active comparator.
Rimegepant was found to be superior to placebo were the percentage of subjects who were pain
free at 2 hours were at doses of 75 mg (31.4%, p=0.002), 150 mg (32.9%, p<0.001), and 300 mg
(29.7%, p=0.002), compared to placebo with 15.3% and rates of adverse events, although mild in
intensity, were dose dependent.17 This trial was not designed with statistical power to allow
comparison of the sumatriptan arm against the rimegepant arm, however the trial did
demonstrate that sumatriptan was also more effective than placebo with respect to the primary
endpoint of pain freedom (35%, p<0.001).17 Furthermore, although the patient numbers were
small, 2% of subjects reported events of chest discomfort, chest pain, and jaw pain all within the
sumatriptan-treated arm. Even the highest dose of rimegepant administered in the trial (600 mg)
did not incur similar events.17 A meta-analysis of 3,827 pooled subjects from four RCTs,
including the three discussed above, supported that 75 mg rimegepant led to significant freedom
from pain (20.6% vs 12.5% for rimegepant vs placebo, Risk Ratio (RR) 1.70, 95% CI 1.39 to
2.08, p<0.001), pain relief (58.6% vs 44.6%, RR 1.34, 95% CI 1.25 to 1.44, p<0.001), and
freedom from MBS (36.0% vs 25.1%, RR 1.44, 95% CI 1.23 to 1.68, p<0.001) at 2 hours postdose compared with placebo.18 Much of the methodology included in this proposal is adopted
from the described empiric trials while improving upon the weaknesses and limitations presented
by them.
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2.5 Review of Methodology
Study Design
In the empiric trials presented above, rimegepant is compared to placebo and subjects
treated a single migraine attack with the active intervention.15,16 Challenges to this study design
emerge on two main accounts with the first being the lack of an active comparator, and the
second being the treatment of only a single attack.
These studies have been critiqued for failing to justify the comparison of rimegepant to
placebo, as opposed to an active comparator, when other therapeutic interventions exist for
migraine. The ethics of the design have been called into question as half of subjects were
allowed to experience severe pain, often resulting in an inability to work or perform typical daily
activities. However, in the setting of a single migraine attack study, long-term harm from a nonactive comparator is unlikely and informed consent can be used to justify the use of a placebo.19
To improve upon ethical standards, this proposed study design includes offering rescue therapies
to all participants to be used 2 hours after administering rimegepant or placebo if needed. Also, if
at any point unbearable pain is experienced, the rescue medication may be self-administered and
will be documented as an intervention failure. Although a non-inferiority design could be used to
compare a new medication with established treatment, it’s difficult to put forth any single
abortive treatment as standard of care. Even the widely used triptans do not lead to response in
33% of patients.16 Another argument is that demonstrating superiority to placebo rather than an
active comparator is more likely to result in positive findings for the medication, but have less of
an impact on therapy choices in clinical practice.19 One RCT compared rimegepant to placebo,
but included sumatriptan (100 mg) as an active comparator. Both rimegepant and sumatriptan
were found to be superior to placebo in freedom from pain at 2 hours, however the trial was not
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designed with statistical power to allow head to head comparison of the sumatriptan arm against
the rimegepant treatment arms.17 Therefore the addition of sumatriptan as an active comparator
without designing the trial with the goal of demonstrating non-inferiority is unlikely to add much
strength to the study results when the primary goal is to compare those on or not on a mAb.
The single-attack study design has been criticized for the lack of generalizability that can
be applied to the efficacy and safety outcomes of the studies because consistency of response to
the medication cannot be assessed.20 The authors do call for future trials to establish the benefits
of rimegepant across multiple attacks, however in defense of this design, studies of single
migraine attacks are the global standard for establishing efficacy of acute treatments of migraine
and for regulatory approval in the US. Multiple-attack studies can be affected by un-blinding
(where patients learn to distinguish active drug from placebo) and carryover effects, so the first
attack is used to define primary efficacy endpoints.20 In order to maintain the randomization and
blinding of a single-attack study but also provide an opportunity to extend results beyond that of
primary efficacy, the multi-phase trial design is proposed to subvert these critiques. For more
detailed information on the proposed study design please refer to 3.1 Study Design.
Study Population
The study population from which subjects are to be recruited consists of adults with
migraine who have been on a stable dose of a CGRP mAb (erenumab, galcanezumab,
fremanezumab, or eptinezumab) for at least 3 months. The CGRP mAbs are administered
monthly (or quarterly for fremanezumab and eptinezumab), none are available generically, and
therefore the medications incur costs to patients, private insurance companies, and government
funded programs. Public paid claims data was used to estimate the number of people in the U.S.
who are on a CGRP mAb for migraine prevention. The most recent data available shows that in
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2019, Medicaid and Medicare Part D spending totaled $48,010,499 and $119,459,268,
respectively, to pay for Aimovig (erenumab-aooe) alone.21,22 Using this data, it can be estimated
that 7,208 and 16,828 patients were covered by Medicaid and Medicare, respectively, for a year
supply of the medication in 2019. With inclusion of those covered for galcanezumab and
fremanezumab, the estimated number of Medicaid and Medicare patients on a CGRP mAb in
2019 totals 42,279 patients. Please refer to APPENDIX A: Study Population Approximation, for
calculations. This is likely a gross underestimation of the number of patients on a mAb currently,
as eptinezumab was not FDA approved until 2020 and the remaining three mAbs were only
approved in 2018.23 For example, with erenumab, there was a 2% increase in spending from
2018 to 2019 for both Medicaid and Medicare, and likely continued to increase by 2021.21 Also,
an even higher growth rate may be expected from 2019 to 2020 in the setting of the Covid-19
pandemic during which a number of patients were transitioned from botulinum toxin therapy to a
mAb for migraine prevention as office visits were made limited.
It is necessary to realize this estimate does not include what is expected to make up the
majority of the study population– the number of patients who obtain a CGRP mAb through
private insurance or a payment assistance program funded by the pharmaceutical company. It is
estimated that 75% of Aimovig prescriptions cost patients $5 or less per month including those
where the Aimovig Ally™ Access Card was used (the card is available to those with private
insurance). The remaining 25% of Aimovig prescriptions cost privately insured patients an
average of $82 per month.24 Although difficult to obtain data to estimate the number of patients
enrolled in the payment assistance program or covered by private insurance, the majority of
patients’ relatively low copay is supportive that cost would be less of a barrier for most US
citizens to be able to access the medication. Based on these data and the calculated estimates
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obtained from it, recruiting patients from the study population in this multi-center US based
study to satisfy the desired sample size is both realistic and attainable. For more detailed
information on recruitment, please refer to 3.4 Recruitment.
Selection Criteria
The selection criteria for subjects to participate in this trial is similar to the rimegepant vs
placebo RCTs and based on International Headache Society (IHS) Guidelines for controlled
trials of acute treatment of migraine attacks in adults. 15-17,25 A complete list of inclusion and
exclusion criteria can be referred to in 3.2 Study Population and Sampling.
One of the most notable exclusion criteria is for subjects with a history with current
evidence of uncontrolled, unstable, or recently diagnosed cardiovascular disease, cerebrovascular
disease, or uncontrolled hypertension. Clinical trials of the mAbs showed cardiovascular safety
issues deemed unrelated to treatment.2 Although no adverse cardiac effects have been observed
thus far in rimegepant vs placebo studies or in the concomitant CGRP mAb and rimegepant case
series, this exclusion criteria is recommended for the purpose of safety.10,13,15,16 CGRP is
important for maintenance of cardiovascular homeostasis and could possibly prevent cerebral or
cardiac ischemia with its induction of vasodilation.2 The limited data surrounding CGRP
blockade by two medications and lack of long-term safety studies make it critical to consider
those with preexisting risk factors in order to prevent a cardiovascular-related adverse event.9
Therefore this population should not be included in this particular study with the knowledge that
as results from long-term safety studies of rimegepant emerge, it may support including
cardiovascular patients in future studies.
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Efficacy Parameters and Outcomes
The primary outcome of freedom from pain at 2 hours and secondary outcomes including
freedom from most bothersome symptom (MBS) at 2 hours, time to freedom from pain etc. are
all seen in the empirical trials of rimegepant vs placebo discussed earlier.15-17 This is fairly
standard in that acute migraine treatment trials which are well designed in accordance with IHS
Guidelines and all have the same, if not similar, efficacy endpoints.25 Where there is variation in
the proposed trial is the addition of the Migraine Specific Quality of Life Questionnaire (MSQ)
to assess the effect of migraine on daily functioning. The MSQ is a psychometrically valid tool
that can be used to reliably measure the impact of migraine among both episodic and chronic
migraine patients. It was found that MSQ change scores were higher in magnitude in groups
experiencing greater decline in headache frequency, e.g. a >50% improvement in headache
frequency correlated with a 23.3 mean change in MSQ score (Standard Deviation (SD) 24.0), 3050% improvement correlated with a 12.6 mean change in MSQ score (SD 20.1), and a <30%
improvement in headache frequency correlated with a 3.0 mean change in MSQ score (SD 14.0)
yielding a p-value of <0.001 for between-category comparisons.26 Although the proposed trial is
focused on acute outcomes from rimegepant intervention, improvements in management of
migraine attacks also has broadened impacts on patients’ functioning and overall quality of life.
If an acute attack is treated more rapidly and with sustained relief, there will be fewer impacts on
daily life activities. Therefore, the inclusion of this questionnaire adds strength to the existing
framework of acute migraine treatment trials.
Outcomes for the proposed study are attained from subjects’ self-reporting through the
use of an electronic Patient Reported Outcomes diary (ePRO diary). This is recommended by
IHS guidelines as an ePRO diary has time-stamp capabilities and also provides an opportunity
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for adverse events (AEs) to be communicated with the research team in real time. Simplicity of
the electronic report form is of the utmost importance, as the quality of collected data decreases
as the quantity increases.25 The goal is for the form to be as easy as possible for subjects to fill
out during attacks. In prior rimegepant studies, an ePRO Diary was exclusively used for outcome
reporting.15,16 However, to remain inclusive of those subjects with significant photophobia as
part of their migraine symptom profile, one may opt for a near-identical paper option so as not to
preclude their ability to report outcomes. Also, during the Run-in Period, all subjects will
practice documenting their symptoms in the diary with acute attacks. Those who are unable to
consistently document, will be excluded from further participation in the trial.
Additionally, participant-reported outcomes come with concerns of report bias. The
subjective interpretation of symptoms and pain severity level will inevitably vary from person to
person. However, with the simple, standardized numerical pain scale (0 = No pain, 1 = Mild
pain, 2 = Moderate pain, or 3 = Severe pain) recommended by IHS guidelines, there is less room
for major variations in subject reporting.25 Furthermore, the open-label secondary phase of the
proposed study will allow for within-subject comparisons, wherein subjective pain ratings will
be more consistent across multiple attacks for each subject. Lastly, the primary endpoint of
freedom from pain is more easily defined than a reduction in pain which involves more
subjective judgement (i.e. the difference between no pain and any degree of pain is binary,
whereas the difference between mild and moderate or moderate and severe pain is not as
explicit). Therefore the efficacy parameters themselves are protective against potential selfreport bias.
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2.6 Review of Possible Confounding Variables
Demographics Variables
One demographics variable which may exert an effect on the outcome is sex. Migraine is
up to 3 times more prevalent in women than in men, and women with migraine have more
frequent and severe headache attacks.2 In rodent models, the application of CGRP to the dura
mater induce behavioral responses consistent with headache only in female rats. Females show
significantly lower facial withdrawal thresholds at 3, 5, and 24 hours after injection (p <
0.0001).27 This suggests the CGRP receptor itself is implicated in the higher prevalence of
migraine in women. The difference may be related to hormonal fluctuations e.g. in estrogen and
progesterone, potentially affecting CGRP signaling.2 Although gepants and mAbs have both
been shown as safe and exert an effect in both male and female patients, existing studies lack the
statistical power to assess a potential sex difference in efficacy.2 For the proposed study, a
female to male subject ratio that approximates the migraine population will be sought, serving to
make the findings from this study generalizable to migraine.
Another factor which raised concern for confounding in previous rimegepant trials is
obesity. Women with obesity formed the majority of the study population. This was criticized for
the potential effect it may have on pharmacokinetics, however body-mass index (BMI) was not
found to predict response to rimegepant.15,18,20 Also, as discussed above, migraine is
predominantly a disease of women, and 43% of adults aged 40-59 years are obese.20 For this
study, the research pharmacy will attempt to recruit from a more diversified population in terms
of sex and weight, especially given the multi-center setting, however it is understood that these
imbalances may only account for the natural differences in disease prevalence and thus far have
not shown to make a significant prediction of outcomes.
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Preventive Medications
In prior rimegepant vs placebo studies, subjects were allowed to have been on a stable
dose of a preventive medication for at least 3 months prior to the trial. The results were stratified
dichotomously, with participants answering if they were on a preventive (yes/no), however the
different types of preventive medications the subjects were on are not described.15,16 This could
have confounded outcomes in that some prophylactic medications can reduce severity of acute
migraine attacks more than others.28 This may impact the level of ease with which the migraine
is successfully treated. In the proposed study, subjects are intentionally on mAb preventives (and
allowed to currently be on one additional non-mAb preventive), and controls are allowed to be
on a stable dose of no more than two non-mAb prophylactic medications. Given that 87% of
those with episodic migraine take no preventive medications, it will be attempted to balance the
number of subjects and controls currently on other preventive treatments in order to minimize the
effect of this confounding variable.28 However, given the inclusion criteria requiring 2-8
migraine attacks per month in the 3 months prior to screening and maintained during the Run-in
Period, as long as the subject is meeting this migraine burden, it is less likely the different
preventives will pose an issue of confounding. This also allows the control subjects to be more
representative of the episodic migraine population at large and improve generalizability of this
study’s results.
Migraine Triggers
In terms of the migraines themselves, subjects may have their own identifiable triggers
which tend to induce a migraine, and this is an element which would be difficult to control for in
the proposed study. Common triggers involve disturbances in sleep, exercise, diet, and stress,
with successful management mitigating migraine burden.29 Although subjects will be encouraged
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to minimize major changes to their routine and medications while optimizing healthy habits in
regards to those four pillars, variation will inevitably exist throughout the study. This may not
only influence how often a particular subject has a migraine, but also how hard it may be to treat.
Pharmacologic treatment may not impart relief without simultaneous management of the
particular trigger (i.e. a subject who is sleep deprived, would likely require sleep in addition
medication in order to relieve their migraine).29 Throughout the Secondary Phase of the study,
patterns may be recognized within subjects’ reported symptoms and outcomes as they treat
multiple attacks with rimegepant. This could reveal to the researcher specific underlying triggers
influencing the results. However, it is realized that the differences among subjects in the
prophylaxis and management of their triggers, may confound the outcomes in almost all
migraine studies.
Rimegepant Formulation
With regards to the active intervention, rimegepant is formulated as an oral disintegrating
tablet (ODT) which has been recognized for its fast absorption and time to peak plasma
concentration.15 This must be considered as it has been associated with relatively rapid onset of
relief seen in subjects. Other migraine agents have also prioritized an ODT formulation given
that many patients have associated nausea with acute attacks. This is done with the intention of
increasing speed of absorption and onset of effect while mitigating the effects of migraine on the
gastrointestinal system.30 In the proposed study, the placebo tablet will be designed with the
same taste, shape, and disintegrating properties as the active intervention. Also, pain outcomes
are to be tracked for 24 hours after self-administering the intervention so that not only the rapid
onset but also sustained pain relief is prioritized in the results to demonstrate efficacy.
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2.7 Conclusion
This review of the literature demonstrates the novelty of concomitant use of rimegepant
with CGRP mAb therapy and the necessity for a RCT investigating their combined efficacy and
safety. The studies that investigate the CGRP pathway and potential mechanisms of rimegepant
in the context of the mechanisms of mAbs aid the understanding of how their combined use may
improve pain outcomes. These studies also lead researchers to consider the potential for adverse
events to arise. This information is critical in the design of the proposed study such that it is not
only feasible but also safe. Next, the case series reviewed in this chapter reveal promising results
for concomitant use of the medications, however they lack the number of subjects, blinding, and
randomization to demonstrate efficacy, so each of these areas are addressed in the proposed
methods. Also, previous RCTs demonstrating the safety and efficacy of rimegepant are discussed
in order to highlight portions of the methodology that are to be either replicated or improved
upon to conduct an effective study while reducing bias and confounding where possible. The
review identifies the gap in this area of research and utilizes what information is available to fill
that gap with a RCT that will generate data for the benefit of both providers and the patients for
whom they prescribe migraine therapy.
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CHAPTER 3: STUDY METHODS
3.1 Study Design
This multi-center, biphasic trial will evaluate the safety and efficacy of rimegepant 75 mg
ODT for acute migraine treatment with concomitant anti-CGRP or anti-CGRP receptor mAb for
migraine prevention. The Primary Phase will consist of a randomized, double-blind, placebocontrolled single-attack study, and the Secondary Phase will be a 2 month open label multiattack study.
3.2 Study Population and Sampling
The source population from which the study and control populations will be acquired
consists of adults ages 18-65 years old with at least a 1 year history of migraine with or without
aura. The study population (herein interchangeably referred to as the mAb group) will have been
treated with a stable dose of an injectable anti-CGRP or anti-CGRP receptor monoclonal
antibody: erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), or
eptinezumab (Vyepti) for at least 3 months prior to screening. The control population (herein
referred to as the control group) will include those who have never used anti-CGRP or antiCGRP receptor mAbs. The complete inclusion and exclusion criteria, which have been partially
adopted from a previous clinical trial investigation of rimegepant, can be seen below.1
Inclusion Criteria:
1. Adults ages 18-65 years old with at least a 1-year history of migraine with or without
aura consistent with a diagnosis according to the International Classification of Headache
Disorders, 3rd edition, (ICHD-3, 2018)
2. Age at onset of migraine is <50 years old.
3. History of 2-8 migraine attacks per month in the 3 months prior to the Screening Visit
and maintains this requirement during the Run-in Period.
4. Less than 15 days with headache (migraine or non-migraine) per month in the 3 months
prior to the Screening Visit and maintains this requirement during the Run-in Period.
5. Study subjects: Appropriately administered stable dose of erenumab, galcanezumab,
fremanezumab, or eptinezumab for at least 3 months prior to study.
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Use of other migraine preventives is permitted. Study subjects may be on a stable
dose of no more than one prophylactic agent, as determined by the investigator,
for at least 3 months prior to the study.
6. Control subjects: naïve to an anti-CGRP or anti-CGRP receptor monoclonal antibody.
a) Use of other migraine preventives is permitted. Control subjects may be on a
stable dose of no more than two prophylactic agents, as determined by the
investigator, for at least 3 months prior to study.
7. All subjects should maintain their preventive regimen and not alter it during the study.
8. Patients with contraindications to use of triptans may be included provided they meet all
other study entry criteria.
9. Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital sign
assessment at the Screening Visit. Clinical site may perform a maximum of 2 repeats of
vital sign measurements if the initial measurement is out of range.
10. Women of childbearing potential must be using two acceptable methods of contraception
to avoid pregnancy throughout the study in such a manner that the risk of inducing
pregnancy is minimized for the duration of the clinical study and up to 8 weeks after the
study.
a) Must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
or equivalent units of HCG)
b) Women must not be breastfeeding
a)

Exclusion Criteria:
1. Current use of a gepant for acute migraine treatment
2. Previously participated in an investigational study of a gepant
3. Difficulty distinguishing migraine headache from tension-type or other headache types
4. Has a history of menstrual migraine, migraine aura with diplopia or impairment of level
of consciousness, hemiplegic migraine, retinal migraine, or medication overuse headache
as defined by ICHD-3
5. Has a current diagnosis of new persistent daily headache, trigeminal autonomic
cephalalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3
6. Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to
screening
7. Participation in any other clinical investigation using an experimental drug or other
therapy (e.g. neuromodulatory devices) within 30 days prior to study intervention
administration
8. Participation in a blood or plasma donation program within 60 or 30 days, respectively,
prior to study intervention administration.
9. Positive drug screen for drugs of abuse that in the investigator’s judgment is medically
significant, in that it would impact the safety of the patient or the interpretation of the
study results. In addition:
a) Detectable levels of cocaine, amphetamine, barbiturates and phencyclidine (PCP)
in the drug screen are exclusionary. Patients who are positive for amphetamines
or barbiturates on the urine drug screen may have their urine samples evaluated
for further analysis at the investigator’s discretion to rule out a false positive
result or ask for documentation showing prescribed use (i.e. methylphenidate for
ADHD)
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Detectable levels of marijuana in the initial drug screen are not exclusionary,
however subjects must have a negative test before initiating the Run-in Period and
remain negative throughout the study in order to participate.
10. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months
or patients who have met DSM-V criteria for any significant substance use disorder
within the past 12 months from the date of the Screening Visit
11. Patient history of HIV disease
12. Patient history of Polycystic Ovarian Syndrome (PCOS)
13. Patient history with current evidence of uncontrolled, unstable or recently diagnosed
obstructive sleep apnea (OSA), cardiovascular disease, such as ischemic heart disease,
coronary artery vasospasm, and cerebral ischemia. Patients with Myocardial Infarction
(MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI),
cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to
screening.
14. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however
patients can be included who have stable hypertension and/or diabetes for 3 months prior
to being enrolled)
15. Patient has a current diagnosis of major depression, other pain syndromes, psychiatric
conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other
than migraine) that, in the investigator’s opinion, might interfere with study assessments
16. Patient has a history of gastric, or small intestinal surgery, or has a disease that causes
malabsorption
17. Has a history or current evidence of any significant and/or unstable medical conditions
(e.g. congenital heart disease or arrhythmia, known or suspected infection, cervical
disease, End Stage Renal Disease, hepatitis B or C, or cancer) that in the investigator’s
opinion, might interfere with study assessments or place the patient at higher risk of a
significant adverse event.
18. ECG and Laboratory Test Findings
a) Estimated glomerular filtration rate (eGFR) according to the re-expressed
abbreviated (four-variable) Modification of Diet in Renal Disease (MDRD) Study
equation ≤ 40 ml/min/1.73m2
b) Corrected QT interval > 470 msec (QTc by method of Frederica), during the
Screening/Baseline Phase
c) Left Bundle Branch block
d) Right Bundle Branch Block with a QRS duration ≥ 150 msec.
e) Intraventricular Conduction Defect with a QRS duration ≥ 150 msec.
f) Serum bilirubin (Total, Direct and Indirect) > 1 x ULN (Only abnormal values of
between 1-1.5x ULN may be repeated once for confirmation during the screening
period.)
g) AST (SGOT) or ALT (SGPT) > 1 x ULN (Only abnormal values of between 11.5x ULN may be repeated once for confirmation during the screening period.)
h) Neutrophil count ≤ 1000/µL (or equivalent).
19. Prohibited concomitant medication prior to randomization and during the course of the
study or as specified.
a) St. John’s Wort should not be taken 14 days prior to randomization and
throughout the study.
b)
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History of use of ergotamine medications on greater than/equal 10 days per month
on a regular basis for greater than/equal 3 months
c) History of non-narcotic analgesic intake on greater than/equal 15 days per month
for greater than/equal 3 months
d) Use of narcotic medication, such as barbiturates, heroin, opium in the form of
morphine and codeine, oxycodone and hydrocodone for at least 2 days prior to
randomization.
e) Use of acetaminophen or acetaminophen containing products after randomization
is prohibited, except as rescue medication as described in protocol. Any use of
acetaminophen or acetaminophen containing products during screening must be
stopped at least 2 days prior to randomization.
b)

3.3 Subject Protection and Confidentiality
Written informed consent must be obtained from the patient in accordance with
requirements of the study center’s institutional review board (IRB) or ethics committee, prior to
the initiation of any protocol-required procedures. The consent forms will be available in
English, Spanish, and translated into additional languages as necessary. The consent form
contains a study description, explanation of the purpose of the research, duration of participation,
potential risks and benefits, methods of protecting confidentiality, a clear statement that
participants may withdraw at any time, and a statement that the investigators reserve the right to
terminate a subject’s involvement at any time. All subjects will be informed if significant new
findings develop during the course of the study that may affect whether they are willing to
continue participation. The consent form will be explained to each subject individually and
privately by research personnel and participants will be given the opportunity to ask questions
and discuss concerns prior to issuing consent (APPENDIX B: Sample Informed Consent Form).
At the time of enrollment, immediately after written informed consent is obtained and
before performing any study-related procedures, each subject will be assigned a unique
sequential 4-digit subject number beginning with 0001, 0002, 0003, etc. for identification
throughout the study. This subject number must not be reused for any other participant in the
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study. Each subject will be provided with an electronic Patient Reported Outcomes (ePRO)
Diary on a secure handheld electronic device to ensure stored data is only shared with the
research team throughout the study. The device will be returned at the trial’s conclusion for
proper de-identification and disposal of subject data. The method of blinding investigators and
subjects as well as the collection and storage of health information obtained both in clinic and
electronically will comply with all relevant privacy standards and regulations as written in the
Health Insurance Portability and Accountability Act (HIPAA). All study personnel will complete
HIPAA training.
The study protocol is written in accordance with the most recently updated Guidelines of the
International Headache Society (IHS) for controlled trials of acute treatment of migraine attacks
in adults: fourth edition.2 This ensures the protection of subjects as the guidelines were created to
allow for a safe, standardized, and evidence-based approach to the conduct of randomized
controlled trials within this specific discipline.
3.4 Recruitment
Subjects will be recruited through outpatient offices, online advertising, and word of
mouth. At sites involved with the study, healthcare providers will provide a brochure and refer
potential participants to contact the research coordinator, who will arrange for a phone screening
based on the inclusion and exclusion criteria (see APPENDIX C: Phone Screening Questions).
Eligible candidates will be brought in for in-person screening and if they continue to meet the
remaining criteria, they will be given the opportunity to enroll in the study and provide written
informed consent. Participants will be continuously enrolled until reaching the target sample
size, and participants will begin the study as recruitment ensues.
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3.5 Timeline and Resources
Based on previous studies involving similar populations with more subjects, the
enrollment period is expected to span approximately 12 months to achieve the target sample size
including both subjects on a CGRP mAb and control subjects who have never used a CGRP
mAb.1 For each enrolled subject, a Run-in Period of 4 weeks, the Primary Phase of 1 to 8 weeks,
and the Secondary Phase of 8 weeks, totals a 13-20 week time commitment. Accounting for
enrollment and the length of data collection, study completion will be within 2 years.
Study materials and personnel required to carry out the study include:
-

Co-primary investigators, 2 research assistants

-

Site coordinator, 1 research assistant, and 1 LPN or RN (for each site)

-

Research pharmacy responsible for balancing demographics variables during
recruitment, use of randomization software, and blinded allocation of intervention in
blister packs

-

Informational brochure for recruitment (see APPENDIX D: Recruitment Brochure)

-

Electronic Patient Reported Outcomes ePRO Diary, a secure hand held electronic
device for each subject with instructions for use (or alternative paper version of
reported outcomes diary)

-

Laboratory kits and laboratory manual
o Safety laboratory, plasma, serum, instructions for all specimens collected will
be provided by a designated central laboratory.

-

ECG Machine, electronic blood pressure monitor, thermometer, scale
o Equipment, supplies, instructions, and training materials will be supplied by a
centralized medical supplies vendor.

32

-

Migraine-Specific Quality of Life Questionnaire (MSQ) electronic or paper forms
(see APPENDIX E: Migraine Specific Quality of Life Questionnaire (MSQ))

-

Serious Adverse Event (SAE) case report forms

-

Investigator brochure for information on rimegepant

Biohaven Pharmaceuticals, Inc. will sponsor the study. The company will provide rimegepant 75
mg ODT and blinded placebo tablets, as well as additional funding support. A fully executed
Data Use Agreement (DUA) is in place between Biohaven and the primary study site.
3.6 Study Protocol and Intervention
Run-in Period
Subjects who have been screened and consented will enter a Run-in Period for 4 weeks
during which migraine frequency will be monitored with a requirement of 2-8 migraine attacks
during the period in order to continue on in the study. They will also have baseline safety
measurements assessed: Physical examination, vital signs/ physical measurements, clinical safety
laboratory testing, ECG, assessment of migraine history (signs and symptoms), and pregnancy
test (See APPENDIX F: Safety Assessments). To document each migraine attack during the
Run-in Period, the participant will use a provided electronic Patient Reported Outcomes (ePRO)
Diary via secure handheld electronic device with time stamping capability which will prompt
documentation of pain, symptoms, and adverse events in the same way it will during the study.
Subjects may use their personal standard of care abortive treatments for each attack. This will
allow the participants to adjust to using the ePRO Diary and assess procedural compliance. Noncompliant subjects and those who do not meet the required number of migraine attacks will be
excluded from further participation in the study. Those who will go on to randomization and
allocation will be administered a baseline Migraine-Specific Quality of Life Questionnaire
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(MSQ). The MSQ is a self-administered, migraine-specific, 14-item instrument assessment of
quality of life that was developed to assess the effect of migraine on daily functioning (see
APPENDIX E: Migraine Specific Quality of Life Questionnaire (MSQ)).
Intervention
The intervention is single dose (75 mg) oral disintegrating rimegepant (Nurtec-ODT
[Biohaven Pharmaceuticals, New Haven, CT] for abortive treatment of migraine attacks of
moderate or severe intensity. The placebo is an oral disintegrating tablet identical in appearance,
taste, and dissolution quality as the rimegepant tablet. Subjects will be educated on how to
properly allow the tablet to dissolve orally and no more than one tablet may be administered
every 24 hours.
Randomization and Assignment of Intervention
For the Primary Phase of the study, subjects in both the mAb group and the control group
will be randomly assigned by a computer program in a 1:1 ratio to rimegepant or placebo for
treatment of a single migraine attack of moderate or severe pain intensity. Both investigators and
participants will be blinded as to their assignments. A blister pack containing a single tablet
(rimegepant or placebo) will be provided to each subject by the research pharmacy. This phase
extends for a maximum of 8 weeks, and those who do not have a migraine attack during that
period will be excluded from further participation in the study. Those who treat their single
attack prior to the 8 week mark may advance to the Secondary Phase.
For the Secondary Phase of the study, beginning after the subject treats their first attack,
all subjects in both groups will receive rimegepant to treat multiple migraine attacks of moderate
or severe pain intensity over an 8 week period. A blister pack containing twelve 75 mg
rimegepant tablets will be provided initially. Some subjects may have more frequent attacks than
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others and require more medication, so they will be instructed to notify the research pharmacy
when they have four tablets remaining and an additional allotment of four tablets can be shipped
to them, with a maximal allotment of 16 tablets total for the 8 week period (accounting for a
maximum of 8 migraine attacks per month).
Table 1. Study Protocol Timeline
Group

Run-in Period
4 weeks

Control
Monoclonal Antibody

Primary Phase (Blinded)
1 migraine attack
Rimegepant
Placebo
Rimegepant
Placebo

Secondary Phase (Open Label)
8 weeks
Rimegepant
Rimegepant
Rimegepant
Rimegepant

3.7 Data Collection
At the time of a migraine attack, subjects will begin documentation in their ePRO Diary.
The first question will be to rate their pain on a numerical rating scale from 0-3, where 0 is no
pain, 1 is mild pain, 2 is moderate pain, and 3 is severe pain. If a subject rates their pain a 2 or 3
(moderate or severe) one will be asked additional questions via the ePRO Diary regarding
specific symptoms (see Table 2) before being prompted to self-administer the allocated tablet to
treat the attack. If a subject rates their pain a 1 (mild), one will be asked to refrain from selfadministering the allocated treatment and only if the pain increases to a 2 or 3 will the patient
restart the documentation process in the ePRO Diary and proceed with treatment. If a subject
takes their own medication (i.e. ibuprofen, acetaminophen etc.) at the time where pain was a
level 1 and has now increased to a 2 or 3, they are not to administer the allocated treatment and
this migraine attack cannot be included in the study.
Once the subject has self-administered the allocated treatment, the ePRO Diary will
prompt to reevaluate symptoms and pain at 30 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours,
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4 hours, 8 hours, 12 hours, 24 hours (see Table 2). There will be an option to report adverse
events at any time during the study (and within 30 days of discontinuation of the trial). This will
include documentation of event severity (mild, moderate, severe), time of onset (ePRO Diary
will automatically timestamp entry), and time of resolution. In addition, subjects will be
instructed to directly contact study personnel for any adverse event with potentially serious
implications (e.g., chest pain, uncontrolled vomiting) within 24 hours. Subjects will be provided
a 24 / 7 contact telephone number to call for such events. All adverse events deemed to be
serious, as determined by the study investigator, will be followed to resolution or stabilization.
All serious adverse events (SAEs) will be reported to the IRB within 72 hours (see APPENDIX
F: Safety Assessments).
To maintain ethical standards, subjects who do not experience freedom from pain 2 hours
after administering the allocated treatment during either phase of the trial will be allowed to use
an approved rescue medication. Permissible rescue medications are aspirin, ibuprofen, naproxen,
other nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen (up to 1000 mg/day),
antiemetics (e.g. metoclopramide or promethazine), triptans, or baclofen. Other rescue
medications may be deemed acceptable by the co-primary investigators on a case by case basis at
the start of the trial. If a subject experiences unbearable pain prior to 2 hours and uses a rescue
medication, this will be considered a treatment failure. If needed, after 48 hours of administering
the study medication, patients may take their standard of care abortive medication(s) (including
triptans if not contraindicated). Use of a rescue medication must be documented in the ePRO
Diary at the time of administration.
After a subject has treated their first migraine attack with the allocated intervention
(rimegepant or placebo), one will return to clinic for safety assessment evaluation within the
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week of treatment (see APPENDIX F: Safety Assessments). If safety is assured, subjects will
move on to the Secondary Phase and be given their blister pack of twelve 75 mg rimegepant
tablets. Once again, subjects are only to treat migraine attacks of moderate or severe pain with
one tablet and will document in their ePRO Diary as they did during the first attack with each
subsequent attack. For the purposes of this study, 48 hours of freedom from moderate (2) or
severe (3) pain between migraine attacks treated with rimegepant or a rescue medication is
required.
Throughout the Secondary Phase, a period of 8 weeks total, subjects will be monitored
for adverse events continuously via the ePRO Diary and as described above, all adverse events
that might potentially be serious must be reported directly to study personnel. Subjects will
return to clinic for safety endpoint measurements at 2 weeks, 4 weeks, and 8 weeks. A MigraineSpecific Quality of Life Questionnaire (MSQ) will be administered electronically at 4 weeks and
8 weeks (see Table 3). Adherence to ePRO Diary reporting and questionnaire response will be
monitored throughout the study and additional reminders will be delivered electronically to those
subjects who are consistently failing to report data.
Table 2. ePRO Diary Prompts and Time Points
eDiary Prompts
Pain rating (0-3)
Identify most bothersome symptom
Phonophobia (0-3)
Photophobia (0-3)
Nausea (0-3)

Before intervention
x
x
x
x
x

30 minutes
x

60 minutes
x

90 minutes
x

2 hours
x

Time since intervention
3 hours
4 hours
x
x

8 hours
x

12 hours
x

24 hours
x

x
x
x

Table 3. Outcome Tracking
Outcome
Tracking
ePRO Diary
MSQ
Safety
Endpoints

Run-in Period
4 weeks
w/ attacks
End of week 4

Primary Phase (Blinded)
1 migraine attack
w/ attack

Secondary Phase (Open Label)
8 weeks
w/ attacks
End of weeks 4 and 8

Screening (Day -1)

After attack

End of weeks 2, 4, and 8 (formally);
potentially serious adverse events
reported any time
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3.8 Outcome Measures
The primary outcome is freedom from pain at 2 hours after the intervention dose.
Freedom from pain will be defined by the presence of no pain (0) in a person who had pain of
moderate (2) or severe (3) intensity immediately prior to administration of the dose. Incidence
proportions will be analyzed with a chi-square. A secondary outcome will be time to freedom
from pain, defined in the same way, and analyzed with a Kaplan-Meier test. Operationalization
and statistical analysis of all primary and secondary outcomes are shown in Table 4.
Several additional secondary outcomes will be measured for all subjects. One secondary
outcome is freedom from most bothersome symptom (MBS) at 2 hours with the MBS having
been identified just prior to administration of the dose. Another set of secondary outcomes
include pain relief at 2 hours and time to pain relief where pain relief is defined as mild (1) or no
pain (0) in a subject who had pain of moderate (2) or severe (3) intensity just prior to
administration of the dose. In addition, total migraine freedom at 2 hours which is defined as
having no pain, nausea, photophobia, and phonophobia at the 2 hour time point will be measured
in all subjects regardless of their initial endorsement of each individual symptom. Use of a rescue
medication after 2 hours and use of a rescue medication before 2 hours (treatment failure) are
also secondary outcomes. Also, MSQ scores will be compared and used as a secondary outcome.
The following secondary outcomes will be measured conditionally, depending on the
responses of the subject in their ePRO Diary. Specific migraine symptoms will be assessed with
freedom from phonophobia at 2 hours, freedom from photophobia at 2 hours, and freedom from
nausea at 2 hours. These will be measured in those who marked the symptom as moderate (2) or
severe (3) prior to dose administration and after 2 hours mark the symptom as absent (0).
Sustained pain freedom will also be measured in those who had pain freedom at 2 hours, and
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defined as remaining pain free from 2 to 24 hours after administering treatment without use of a
rescue medication.
Table 4. Operationalization and Planned Statistical Analysis of Primary and Secondary Outcomes

Outcome
Freedom from pain at 2 hours
Time to freedom from pain
Freedom from MBS at 2 hours
Pain relief at 2 hours
Time to pain relief
Freedom from phonophobia at 2
hours
Freedom from photophobia at 2 hours
Freedom from nausea at 2 hours
Total migraine freedom at 2 hours
Use of rescue medication after 2
hours
Use of rescue medication before 2
hours (treatment failure)
Sustained pain freedom from 2-24
hours
MSQ Scores

Operationalization
Dichotomous
Continuous
Dichotomous
Dichotomous
Continuous
Dichotomous

Type of Statistical Analysis
Chi-square
Kaplan Meier
Chi-square
Chi-square
Kaplan Meier
Chi-square

Dichotomous
Dichotomous
Dichotomous
Dichotomous

Chi-square
Chi-square
Chi-square
Chi-square

Dichotomous

Chi-square

Dichotomous

Chi-square

Continuous

Between group minimally
important differences

3.9 Sample Size Calculation
One RCT found that the incidence proportion of freedom from pain at 2 hours was 10.9% of
those who had taken placebo and 21.2% in those who had taken 75 mg of rimegepant.3 The effect
size (absolute difference of effect) is 10.3%. With a 2-sided significance level of 0.05 (α), and 80%
power, a minimum sample size of 420 participants was calculated. This yields a sample of 210 in
the mAb group and 210 in the control group. The projected minimum sample size will further
consider the anticipation of drop out and discontinuation during the study. The previously
mentioned trial had a dropout and discontinuation rate of 7.1%. To account for anticipated loss
during the study period, a sample size of 450 subjects will be sought: 225 subjects in the mAb group
and 225 subjects in the control group. (See APPENDIX G: Sample Size Calculation)
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3.10

Analysis
Variables to describe the population at baseline will be balanced between the mAb group

and the control group. This will include age, sex, race, ethnicity, and BMI. This will also include
migraine type in terms of with aura or without aura. Dichotomous variables will be represented
with counts and percentages. Continuous variables will be summarized with univariate statistics
(e.g., n, mean, standard error, median, minimum and maximum).
Several populations will be analyzed. Enrolled subjects include those who sign an
informed consent form and are assigned a subject identification number. Randomized subjects
are enrolled subjects who receive a randomization treatment assignment during the Primary
Phase (rimegepant or placebo). Treated subjects are enrolled subjects who receive study therapy
(rimegepant or placebo). Modified Intent to Treat (mITT) subjects are randomized subjects that
take any amount of study therapy and provide at least one efficacy measurement.
Analysis will be performed with a modified intention-to-treat method. Results will be
statistically significant if p < 0.05. The primary outcome is freedom from pain at 2 hours,
analyzed via chi-square statistical test between mAb and control groups. Secondary outcomes,
both dichotomous and continuous variables, and their appropriate statistical tests for analysis are
listed in Table 4.
Exploratory analysis will be performed within subjects who were randomized to receive
placebo during the Primary Phase and then subsequently administered rimegepant in the
Secondary Phase. A McNemar’s test will be used to compare outcomes within the same subject.
The same test will be used to analyze each subject’s consistency of response to rimegepant over
the course of the Secondary Phase. Lastly, a stratified analysis will compare the response to
rimegepant seen in positive versus less positive responders to preventive mAbs.

40

REFERENCES
1.
2.

3.

Lipton RB, Croop R, Stock EG, et al. Rimegepant, an Oral Calcitonin Gene-Related
Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142-149.
Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache
Society for controlled trials of acute treatment of migraine attacks in adults: Fourth
edition. Cephalalgia. 2019;39(6):687-710.
Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant
orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3,
double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745.

41

CHAPTER 4: CONCLUSION
4.1 Advantages and Disadvantages
The primary advantage of the proposed study is well defined in the statement of the problem
as it fills the gap in the investigation of concomitant use of rimegepant with a CGRP mAb through a
randomized controlled trial. The proposed methods are valid as they were written in accordance
with International Headache Society (IHS) guidelines and mirror previous rimegepant vs placebo
RCTs, however improvements have also been made in the proposed study design. With its unique
biphasic design, this trial is able to maintain a phase with blinding and randomization to investigate
a single migraine attack while also meeting ethical guidelines in a separate phase allowing the
investigation of rimegepant’s effects in the acute treatment of several migraine attacks over time.
Furthermore, the addition of the Migraine-Specific Quality of Life Questionnaire (MSQ) provides a
more comprehensive measurement of the medication’s impact on patients’ overall migraine
management. The study is powered appropriately and the sample size is sufficient in comparison to
previous rimegepant vs placebo RCTs. Compared to the case series for concomitant rimegepant and
CGRP mAb, the sample size is significantly larger. Lastly, a strength of this study is its
generalizability. Although the selection criteria are necessarily strict because rimegepant is still a
fairly new medication, the recruitment of subjects such that the sample emulates the study
population at large is highly prioritized. The generalizability is also improved by the multi-attack
phase of the study, where consistency of response to rimegepant may be analyzed. This may also be
helpful in its application to studies of other members of the gepant class for treatment of acute
migraine attacks in the future.
A potential disadvantage of this study is the confounding variables it poses which are
difficult to control for. These include patient specific migraine triggers and environmental changes,
which are present in any migraine treatment study, and therefore expected to arise in this trial.
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However, an emphasis to patients about maintaining their routines is all that can be realistically
achieved to address this variable. Second, variability in the types of preventives the control subjects
are taking poses a potential confounding variable, however in order to maintain the external validity
of the study it is necessary to include subjects on preventives for their migraines. Lastly, the
proposed study does not include an active comparator, with rimegepant being compared to placebo.
It might be argued that the inclusion of an active comparator (e.g. a triptan) would strengthen the
clinical implications of the study results, however it is beyond the scope of this trial which is
primarily focused on comparing the effects and safety of the drug in those taking vs not taking a
CGRP mAb. Depending on results from this study, the inclusion of an active comparator in similar
future studies might be warranted.
4.2 Clinical and Public Health Significance
The findings from this study have the potential to impact patients and their providers as
well as lead to public health benefits. Both preventive and abortive treatment of migraine are
addressed in this trial, which are the two pillars of migraine management. The main objective is
to determine the efficacy of rimegepant with outcome measures focused on pain and symptom
freedom in the acute setting, however it is the incorporation of the medication in long-term
migraine management that expands the impacts of this study. Patients’ quality of life is
implicated since an improved migraine treatment regimen leads to less time in pain, fewer
disability work days, and less time spent being treated in a healthcare setting. This also has
impacts on the healthcare system at large, as the total estimated cost of migraine headache
amounts to $78 billion per year in the US.1 The estimated mean cost for migraine-related care
per outpatient visit was $139.88, per Emergency Room (ER) visit was $775.09, and per inpatient
hospitalization was $7,317.07.2 It is cost saving to both the patient and to the health system when
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there are fewer visits to the ER and fewer hospitalizations related to migraine care. The proposed
study’s results may expand evidence based management options which would help patients treat
their migraine attacks at home, decreasing the need for emergency visits and inpatient stays.
Given the increasing use of mAbs for preventive therapy, understanding the efficacy and
safety of rimegepant in patients taking such preventives is an important consideration. This study
will provide data helping to elucidate where rimegepant best fits in migraine management and
for which subset of patients a benefit is likely to be achieved. With the potential to improve the
lives of patients, providers will be able to refer to data from a randomized controlled trial before
prescribing their patients concomitant rimegepant and CGRP mAb to understand the likely
benefits, and risks, associated with their use.
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APPENDICES
APPENDIX A: Study Population Approximation
Calculations approximating study population using paid claims data from Medicaid and
Medicare Part D spending reports:
Aimovig (erenumab-aooe)
Medicaid
Total spending in 2019: $48,010,499
Average spending per dosage unit: $559.84
Doses per person, in one year: 12
48,010,499 ÷ 559.84 = 85,758
85,758 ÷ 12 = 𝟕, 𝟏𝟒𝟔 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔

Medicare Part D
Total spending in 2019: $119,459,268
Average spending per dosage unit: $591.54
Doses per person, in one year: 12
119,459,268 ÷ 591.54 = 201,946
201,946 ÷ 12 = 𝟏𝟔, 𝟖𝟐𝟖 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔

Emgality (galcanezumab-Gnlm)
Medicaid
Total spending in 2019: $23,788,338
Average spending per dosage unit: $554.80
Doses per person, in one year: 12
23,788,338 ÷ 554.80 = 42,877
42,877 ÷ 12 = 𝟑, 𝟓𝟕𝟑 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔

Medicare Part D
Total spending in 2019: $40,700,935
Average spending per dosage unit: $588.61
Doses per person, in one year: 12
40,700,935 ÷ 588.61 = 69,147
69,147 ÷ 12 = 𝟓, 𝟕𝟔𝟐 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔

Ajovy (fremanezumab-Vfrm)
Medicaid
Total spending in 2019: $12,806,446
Average spending per dosage unit: $373.95
Doses per person, in one year: 12
12,806,446 ÷ 373.95 = 34,246
34,246 ÷ 12 = 𝟐, 𝟖𝟓𝟑 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔

Medicare Part D
Total spending in 2019: $28,888,525
Average spending per dosage unit: $393.51
Doses per person, in one year: 12
28,888,525 ÷ 393.51 = 73,412
73,412 ÷ 12 = 𝟔, 𝟏𝟏𝟕 𝒑𝒂𝒕𝒊𝒆𝒏𝒕s

Total number of patients covered by Medicaid or Medicare Part D in 2019 for a year
supply of CGRP mAb migraine preventive
7,146 + 16,828 + 3,573 + 5,762 + 2,853 + 6,117 = 𝟒𝟐, 𝟐𝟕𝟗 𝒑𝒂𝒕𝒊𝒆𝒏𝒕𝒔
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APPENDIX B: Sample Informed Consent Form
COMPOUND AUTHORIZATION AND CONSENT FORM FOR PARTICIPATION IN A
RESEARCH STUDY
YALE UNIVERSITY
YALE UNIVERSITY SCHOOL OF MEDICINE, PHYSICIAN ASSOCIATE PROGRAM
Study Title: EFFICACY OF RIMEGEPANT PLUS CALCITONIN GENE-RELATED
PEPTIDE MONOCLONAL ANTIBODY FOR MIGRAINE
Principal Investigator(s): [Names here]
Introduction
You are being asked to join a research study. The following information will explain the purpose
of the study, what you will be asked to do, and the potential risks and benefits. You should ask
questions before deciding whether you wish to participate, or at any time during the course of the
study.
Purpose
The purpose of this research study is to investigate the effectiveness of rimegepant (a medication
indicated for treating acute migraine attacks) in the setting of use of a calcitonin gene-related
peptide (CGRP) monoclonal antibody (erenumab, galcanezumab, fremanezumab, or
eptinezumab; indicated for the prevention of migraine attacks).
Procedures
This study involves 6 in-person visits over a 13-20 week time period. The first visit will include
Safety Assessments: a physical examination, vital sign/ physical measurements, blood draws, an
electrocardiogram (ECG), pregnancy test (if applicable), and questions about your migraine
history of signs and symptoms. Then a Run-in Period (4 weeks) will begin during which you will
use an electronic Patient Reported Outcomes (ePRO) Diary which will prompt you to document
pain, symptoms, and adverse events at the time of a migraine attack (detailed explanation
below). You may use your personal standard of care abortive treatments for each migraine attack
during this period. Subjects who are unable to document appropriately may be excluded from
further participation in the study.
Preparation and Primary Phase
The second visit you will be asked to complete a Migraine-Specific Quality of Life
Questionnaire (MSQ), a 14 item assessment that was developed to assess the effect of migraine
on daily functioning. You will be randomly assigned to receive either a single dose (75 mg) of
oral disintegrating rimegepant (Nurtec-ODT) or an identical placebo in a blister pack to be used
to treat a single migraine attack of moderate or severe pain intensity. You and the researchers
will not know which treatment you are assigned. This first phase of the study extends for a
maximum of 8 weeks. Those who do not have a migraine attack during that period will be
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dismissed from further participation in the study. Those who treat their single attack prior to the
8 week mark may advance to the Secondary Phase.
Secondary Phase
The third visit, after your first treated migraine attack, you will return for Safety Assessments. In
the Secondary Phase of the study, you will receive rimegepant to treat multiple migraine attacks
of moderate or severe pain intensity over an 8 week period. A blister pack containing twelve 75
mg rimegepant tablets will be provided initially. Some subjects may have more frequent attacks
than others and require more medication, so you will be instructed to notify the research
pharmacy for more tablets if needed. You will have in-person visits at the end of weeks 2, 4, and
8 during which Safety Assessments will be repeated and the MSQ will be administered at the 4
and 8 week visits.
ePRO Headache Diary
At the time of a migraine attack, you will begin documentation in your ePRO Diary. The first
question will be to rate your pain on a rating scale from 0-3, where 0 is no pain, 1 is mild pain, 2
is moderate pain, and 3 is severe pain. If you rate your pain a 2 or 3 (moderate or severe) you
will be asked additional questions via the ePRO Diary regarding specific symptoms (most
bothersome symptom, nausea, light sensitivity, and sound sensitivity) before being prompted to
take your pill (rimegepant or placebo) to treat the attack. After you take the pill, the ePRO Diary
will prompt you to reevaluate your symptoms and pain at 30 minutes, 60 minutes, 90 minutes, 2
hours, 3 hours, 4 hours, 8 hours, 12 hours, 24 hours. There will be an option to report side effects
or other adverse events at any time during the study (and in the 30 days after you complete the
study) and you will be encouraged to document them at the times they start and end (ePRO Diary
will automatically timestamp the entries).
Subjects who do not experience freedom from pain at 2 hours after taking the treatment or have
unbearable pain prior to 2 hours will be allowed to use an approved rescue medication. This must
be documented in the ePRO Diary at the time you take it.
Potential Risks
There are some risks associated with participation in this study. These risks include (1)
rimegepant, (2) phlebotomy, and (3) confidentiality.
(1) Rimegepant
Although uncommon, documented adverse reactions to rimegepant include nausea (23%), abdominal pain (< 2%), dyspepsia (< 2%), and <1% risk of skin rash,
hypersensitivity reaction, or dyspnea.1
Minimizing risk: Patients with serious medical conditions are not permitted to take part in
the study.
(2) Phlebotomy
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Possible risks associated with blood draws (as part of Safety Assessments) include pain,
bleeding, fainting, bruising, infection, and/or hematoma at the injection site.
Minimizing Risk: Only trained professional phlebotomists and nursing staff will perform
blood draws.
(3) Confidentiality
Taking part in any research study places you at risk for loss of confidentiality. Several
procedures are in place to reduce this risk (see below).
1

Nurtec ODT (rimegepant) [prescribing information]. New Haven, CT: Biohaven
Pharmaceuticals Inc.; May 2021.
Potential Benefits
This research may benefit you directly in the treatment of your acute migraine attacks. Even if
you do not directly benefit from taking part in the study (e.g., if you get placebo or rimegepant is
not effective for you), the results will serve to improve our understanding of the effectiveness of
rimegepant in migraine patients.
Privacy/ Confidentiality
To protect your confidentiality, your name and other identifying information will not be recorded
on any study documents. At the time of enrollment, immediately after written informed consent
is obtained and before performing any study-related procedures, you will be assigned a unique 4digit subject number for identification throughout the study. The method of blinding
investigators and subjects as well as the collection and storage of health information obtained
both in clinic and electronically will comply with all relevant privacy standards and regulations
as written in the Health Insurance Portability and Accountability Act (HIPAA). We will only
collect information that is needed for research. Only the researchers involved this study and
those responsible for research oversight will have access to the information you provide.
Examples of information that we are legally required to disclose include certain reportable
diseases and Serious Adverse Events.
Research Authorization: Except as permitted by law, your health information will not be
released in an identifiable form outside of the Yale University research team. Examples of
information that we are legally required to disclose include abuse of a child or elderly person, or
certain reportable diseases. Note, however, that your records may be reviewed by those
responsible for the proper conduct of research such as the Yale University Human Research
Protection Program, Yale University Human Subjects Committee. The information about your
health that will be collected in this study includes: age, gender, weight, height, race, admission
diagnosis, medical comorbidities, length of hospital stay, infectious disease history, antibiotic
use history and presence of indwelling devices. Information may be re-disclosed if the recipients
are not required by law to protect the privacy of the information. At the conclusion of this study,
any identifying information related to your research participation will be destroyed. By agreeing
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to participate in this study, you authorize the use and/or disclosure of the information described
above for this research study. The purpose for the uses and disclosures you are authorizing is to
ensure that the information relating to this research is available to all parties who may need it for
research purposes. This authorization to use and disclose your health information collected
during your participation in this study will never expire.
Voluntary Participation
Taking part in this study is your choice. You can choose to take part, or you can choose not to
take part in this study. You can also change your mind at any time. Regardless of the choice you
make, you will not lose access to your medical care or give up any legal rights or benefits. The
researcher also has the right to discontinue your participation in the study at any time. Take as
much time as you need before you make your decision. Ask the research staff any questions or to
clarify items you do not understand. Once you have an understanding, you will be asked if you
wish to participate, and if so, you will have to sign this form.
Questions
You have read the above description of the research study. You have read the risks and benefits
involved, at this point please ask any further questions you have.
If you have any further questions later or if you have a research-related problem, you may
contact the Principal Investigator(s) at 203-xxx-xxxx.
If you have questions about your rights as a research participant, or you have complaints about
this research, you call the Yale Institutional Review Board at (203) 785-4688 or email
hrpp@yale.edu.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required
by U.S. Law. This Web site will not include information that can identify you. At most, the Web
site will include a summary of the results. You can search this Web site at any time.
Authorization and Permission
Your signature below indicates that you have read this consent document and that you agree to
participate in this study. You will be provided with a copy of this form.
___________________________
Participant Printed Name

___________________________
Participant Signature

______
Date

___________________________
Person Obtaining Consent Printed Name

___________________________
Person Obtaining Consent Signature

______
Date
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Complete if the participant is not fluent in English and an interpreter was used to obtain consent.
Participants who do not read or understand English must not sign this full consent form, but
instead sign the short form translated into their native language. This form should be signed by
the investigator and interpreter only. If the interpreter is affiliated with the study team, the
signature of an impartial witness is also required.
Print name of interpreter: __________________________________
Signature of interpreter: __________________________________
Date: _______
An oral translation of this document was administered to the participant in __________________
(language) by an individual proficient in English and __________________ (language).
Print name of impartial witness: __________________________________
Signature of impartial witness: __________________________________
Date: _______
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APPENDIX C: Phone Screening Questions
“We would like to ask you some general information to determine whether you might qualify for
this study. This information will only be used to determine your eligibility to participate in
research. This information will be stored in secure research files. If you do not want any
information about you stored, we will terminate this interview now. If you agree to proceed
ahead with this preliminary interview and seem to be eligible to participate in this study, we may
invite you for a face to face meeting. Would you like to continue?”
YES/NO
1. Verification of patient identifiers (name, date of birth)
2. How old were you diagnosed with migraine?
3. How many migraine attacks do you have per month? How many migraine attacks have
you had per month for the last 3 months?
4. Do you currently take or have you ever taken any of the following medications:
erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), or eptinezumab
(Vyepti)?
a. If answer is yes:
i. How long have you been taking the medication?
ii. Has your dose changed in the past 3 months?
iii. Do you use any other migraine preventives? How many?
iv. What other medications or treatments do you take?
b. If answer is no:
i. Do you use any migraine preventives? How many?
ii. What other medications or treatments do you take?
5. Do you currently take a gepant (i.e. rimegepant, ubrogepant) to treat migraine attacks?
6. Have you ever participated in an investigational study of a gepant?
7. Have you participated in any other clinical investigation using an experimental drug or
other therapy in the past 30 days?
8. Women of childbearing potential
a. Are you currently pregnant or breastfeeding?
b. Are you planning to become pregnant in the next 6 months?
9. May we have your verbal consent to access your medical records in order to further
assess your eligibility for participation in this study?
In addition to the phone screening questions above, the potential subjects’ medical records will
be reviewed to determine eligibility based on inclusion/exclusion criteria. If met, they will be
brought in for an in-person Screening Visit to determine if enrollment in the study will be offered
to them.
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APPENDIX D: Recruitment Brochure

DO YOU HAVE MIGRAINES?
Do you take erenumab, galcanezumab, fremanezumab, or eptinezumab for
migraine prevention?
OR
Have you NEVER taken erenumab, galcanezumab, fremanezumab, or
eptinezumab?
Volunteers Needed for Participation in a Research Study
(read on for additional information)
Study Purpose: To investigate the
effectiveness of rimegepant (a medication
for treating migraine attacks) with use of a
CGRP monoclonal antibody (erenumab,
galcanezumab, fremanezumab, or
eptinezumab; for the prevention of migraine
attacks).

If you are interested in
participating or have any
questions, please do not hesitate
to contact us at:
203-xxx-xxxx or
xxxxxx@yale.edu

Who can participate?
What will be asked of me?
Adults (age 18-65 years) with at least 1 year
history of migraine and treated for at least 3
months with injectable anti-CGRP or antiCGRP mAb: erenumab (Aimovig),
galcanezumab (Emgality), fremanezumab
(Ajovy), or eptinezumab (Vyepti)

-

-

OR

-

Adults (age 18-65 years) with at least a 1
year history of migraine who have never
taken a CGRP mAb for migraine prevention

-
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You will be asked to take rimegepant
(or placebo) to treat acute migraine
attacks
Document your migraine symptoms
in an electronic diary (or paper
equivalent)
6 in-person visits over a 13-20 week
time period
Receive Safety Assessments: a
physical examination, vital sign/
physical measurements, blood draws,
an ECG, pregnancy test (if
applicable), and answer questions
about your migraine history of signs
and symptoms.

APPENDIX E: Migraine Specific Quality of Life Questionnaire (MSQ)
PATIENT INSTRUCTIONS:
Please fill out this questionnaire. It will help us understand the effects of migraine headache on your daily
activities. The questionnaire has been designed so that it can be completed quickly and easily. Please check only
one answer for each question. You should answer every question. Thank you for your time.
While answering the following questions,
please think about all migraine attacks you may have had in the past
4 weeks
PLEASE SELECT ONLY ONE RESPONSE TO THESE QUESTIONS:
3. In the past 4 weeks, how often have you had
difficulty in performing work or daily activities
because of migraine symptoms?

1. In the past 4 weeks, how often have
migraines interfered with how well you
dealt with family, friends and others who
are close to you?

(Select one response)

(Select one response)















None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

2. In the past 4 weeks, how often have
migraines interfered with your leisure time
activities, such as reading or exercising?

4. In the past 4 weeks, how often did migraines
keep you from getting as much done at work or
at home?

(Select one response)

(Select one response)















None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time
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None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

5. In the past 4 weeks, how often did
migraines limit your ability to concentrate
on work or daily activities?

8. In the past 4 weeks, how often have you had
to cancel work or daily activities because you
had a migraine?

(Select one response)

(Select one response)
 None of the time








None of the time

Some of the time
A good bit of the time
Most of the time
All of the time

6. In the past 4 weeks, how often have
migraines left you too tired to do work or
daily activities?
(Select one response)














A little bit of the time

None of the time








Some of the time
A good bit of the time
Most of the time
All of the time

10.

(Select one response)








Some of the time
A good bit of the time
Most of the time
All of the time

9. In the past 4 weeks, how often did you need
help in handling routine tasks. such as every
day household chores, doing necessary
business, shopping, or caring for others, when
you had a migraine?
(Select one response)

A little bit of the time

7. In the past 4 weeks, how often have
migraines limited the number of days you
have felt energetic?

A little bit of the time

None of the time

None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

In the past 4 weeks, how often did you have
to stop work or daily activities to deal with
migraine symptoms?

(Select one response)

A little bit of the time








Some of the time
A good bit of the time
Most of the time
All of the time
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None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

11. In the past 4 weeks, how often were you
not able to go to social activities such as
parties or dinner with friends because you had
a migraine?

13. In the past 4 weeks, how often have you felt
like you were a burden on others because of
your migraines?
(Select one response)
 None of the time

(Select one response)







12.

None of the time







A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

14.

In the past 4 weeks, how often have you
felt fed up or frustrated because of your
migraines?

Some of the time
A good bit of the time
Most of the time
All of the time

In the past 4 weeks, how often have you
been afraid of letting others down because of
your migraines?

(Select one response)

(Select one response)








A little bit of the time








None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time
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None of the time
A little bit of the time
Some of the time
A good bit of the time
Most of the time
All of the time

APPENDIX F: Safety Assessments
Safety Assessments will be performed at the Screening Visit (Day -1), prior to the Run-in Period,
after the first treated migraine attack in the Primary Phase, and at the end of weeks 2, 4, and 8
during the Secondary Phase.
1) Physical Examination
2) Vital Signs/ Physical Measurements
a. Height will only be captured at the Screening Visit.
b. Weight (BMI), body temperature, respiratory rate, blood pressure, orthostatic
change in blood pressure and heart rate will be collected at all indicated time
points.
3) Clinical Safety Laboratory Testing
a. Hematology
b. Blood chemistry/electrolytes
c. Lipid panel
d. LFTs, bilirubin
e. eGFR
f. Urinalysis
g. Urine drug screen
4) Electrocardiogram (ECG)
5) Assessment of Migraine History (Signs and symptoms)
6) Pregnancy Test
a. A serum pregnancy test will be completed at the Screening Visit and at the
conclusion of the Run-in Period (if appropriate).
b. Confirmatory urine pregnancy test for Women of Child Bearing Potential
(WOCBP) should be completed during remainder of indicated time points.
7) Adverse Event (AE) and Serious Adverse Event (SAE) Assessment
a. Definitions
i. Serious Adverse Event (SAE)- any event that meets any of the following
criteria: death, life-threatening, inpatient hospitalization or prolongation of
existing hospitalization, persistent or significant disability/incapacity,
congenital anomaly/birth defect in the offspring of a subject who received
rimegepant, others may be considered an SAE when, based upon medical
judgement, jeopardize the subject and may require medical or surgical
intervention
ii. Non-Serious Adverse Event (AE)- any unfavorable and unintended sign
(e.g. abnormal laboratory finding), symptom, or disease temporally
associated with the use of the investigational product, whether or not it is
considered related to the investigational product
b. SAEs are reported from the time of informed consent and non-serious AEs are
reported from the time of first dose. All ongoing non-serious AEs and SAEs will
be followed until resolution or until investigator deems there will be no further
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status change. SAE and AE’s that occur during the treatment period should be
reported to the site directly or via ePRO Diary.
c. SAEs, whether related or not related to study drug, and pregnancies must be
reported within 24 hours of the site’s knowledge of the event
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APPENDIX G: Sample Size Calculation

The sample size was calculated* using the following parameters:
Alpha: 0.05 (tails = 2)
Beta: 0.20
Power of 80%
Effect Size for proportions: 21.2% - 10.9% = 10.3%
Factoring in a 7.1% drop out rate, the final sample size is 450 subjects, 225 in mAb group and
225 in control group.

*Calculated using Power and Precision. Version 4.0. Biostat, Inc. Englewood, New Jersey.
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